Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 29;13(2):366.
doi: 10.3390/life13020366.

Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors

Diana Mihalcea  1   2 , Hayat Memis  1 , Sorina Mihaila  1   2 , Dragos Vinereanu  1   2
Affiliations
Review

Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors

Diana Mihalcea et al. Life (Basel). .

Abstract

Cardiotoxicity is an important side effect of vascular endothelial growth factor (VEGF) inhibitors therapy used in the treatment of various malignancies, leading to increased morbidity and mortality. Arterial hypertension, cardiac ischemia with the acceleration of atherosclerosis, arrhythmias, myocardial dysfunction and thromboembolic disease are the most feared cardiovascular adverse reactions due to VEGF inhibitors. Susceptibility for the occurrence of VEGF inhibitors-induced cardiotoxicity has multifactorial determinants, with a significant inter-individual variation. Baseline cardiovascular risk assessment of the patient, type and stage of cancer, dose and duration of VEGF inhibitors treatment and adjuvant chemotherapy or radiotherapy are the main predictors for cardiotoxicity. The role of the cardio-oncology team becomes essential for achieving maximum therapeutic anti-angiogenic effects with minimum cardiovascular side effects. This review will summarize the incidence, risk factors, mechanisms, management and treatment of VEGF inhibitors-induced cardiovascular toxicity.

Keywords: VEGF inhibitors; cancer; cardiovascular toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. [(accessed on 2 December 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer.
    1. Mihalcea D.J., Florescu M., Vinereanu D. Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer. Am. J. Ther. 2017;24:e3–e11. doi: 10.1097/MJT.0000000000000453. - DOI - PubMed
    1. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., ESC Scientific Document Group et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur. Heart J. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211. - DOI - PubMed
    1. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. 2022;43:4229–4361. doi: 10.1093/eurheartj/ehac244. - DOI - PubMed
    1. Lee W.S., Kim J. Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Mol. Cell Toxicol. 2018;14:247–254. doi: 10.1007/s13273-018-0027-z. - DOI

LinkOut - more resources